Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[Here we review the dosage effects and mutations of the proteolipid protein (PLP) gene that causes Pelizaeus-Merzbacher disease (PMD) and spastic paraplegia Type 2 (SPG2) disorders of CNS myelination.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP783484.RAfc5trVL4GEoe-5-oRuCWqmNrc6kOaopR5OfFy29Ee_8130_assertion description "[Here we review the dosage effects and mutations of the proteolipid protein (PLP) gene that causes Pelizaeus-Merzbacher disease (PMD) and spastic paraplegia Type 2 (SPG2) disorders of CNS myelination.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP783484.RAfc5trVL4GEoe-5-oRuCWqmNrc6kOaopR5OfFy29Ee_8130_provenance.
• NP714809.RAdj-LJzDGyma8BFmJzPwEfRDUDWJsR0n_IrGy7U8vn0o130_assertion description "[Here we review the dosage effects and mutations of the proteolipid protein (PLP) gene that causes Pelizaeus-Merzbacher disease (PMD) and spastic paraplegia Type 2 (SPG2) disorders of CNS myelination.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP714809.RAdj-LJzDGyma8BFmJzPwEfRDUDWJsR0n_IrGy7U8vn0o130_provenance.
• NP163891.RAobQ-WbSlgy_dmSlLTgF3RVJWJmIUdgwBzCG9WA2fOJ0130_assertion description "[Here we review the dosage effects and mutations of the proteolipid protein (PLP) gene that causes Pelizaeus-Merzbacher disease (PMD) and spastic paraplegia Type 2 (SPG2) disorders of CNS myelination.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP163891.RAobQ-WbSlgy_dmSlLTgF3RVJWJmIUdgwBzCG9WA2fOJ0130_provenance.
• NP742642.RAfyRucnIXkH8KD97QHv0HVaDiau3Rufk38IGAs7rcefc130_assertion description "[Here we review the dosage effects and mutations of the proteolipid protein (PLP) gene that causes Pelizaeus-Merzbacher disease (PMD) and spastic paraplegia Type 2 (SPG2) disorders of CNS myelination.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP742642.RAfyRucnIXkH8KD97QHv0HVaDiau3Rufk38IGAs7rcefc130_provenance.
• NP483117.RAZ3Uxtg5dMgmO3BtOb-VX-c47nsIQZt0EHISAerqI8jU130_assertion description "[Here we review the dosage effects and mutations of the proteolipid protein (PLP) gene that causes Pelizaeus-Merzbacher disease (PMD) and spastic paraplegia Type 2 (SPG2) disorders of CNS myelination.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP483117.RAZ3Uxtg5dMgmO3BtOb-VX-c47nsIQZt0EHISAerqI8jU130_provenance.
• NP394848.RAIiSjkF_Z6cUd85SqHydzngZsr5TdMx0IAV7fPCJ35-E130_assertion description "[Here we review the dosage effects and mutations of the proteolipid protein (PLP) gene that causes Pelizaeus-Merzbacher disease (PMD) and spastic paraplegia Type 2 (SPG2) disorders of CNS myelination.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP394848.RAIiSjkF_Z6cUd85SqHydzngZsr5TdMx0IAV7fPCJ35-E130_provenance.
• NP927318.RAD6dhASIS8e5s3fzQg9A8B3yCYyGE2bIrSkDjDTZONrQ130_assertion description "[Here we review the dosage effects and mutations of the proteolipid protein (PLP) gene that causes Pelizaeus-Merzbacher disease (PMD) and spastic paraplegia Type 2 (SPG2) disorders of CNS myelination.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP927318.RAD6dhASIS8e5s3fzQg9A8B3yCYyGE2bIrSkDjDTZONrQ130_provenance.
• NP875838.RA-T1TYUDXHPbnQv3vwXJXFIXjk0Rbw5CeJ2bsXWBFTjQ130_assertion description "[Here we review the dosage effects and mutations of the proteolipid protein (PLP) gene that causes Pelizaeus-Merzbacher disease (PMD) and spastic paraplegia Type 2 (SPG2) disorders of CNS myelination.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP875838.RA-T1TYUDXHPbnQv3vwXJXFIXjk0Rbw5CeJ2bsXWBFTjQ130_provenance.
• NP329157.RAC7dwbrnLwJLc7FmdFFy6Rp3hneE3DgixiOyclmG8izA130_assertion description "[Here we review the dosage effects and mutations of the proteolipid protein (PLP) gene that causes Pelizaeus-Merzbacher disease (PMD) and spastic paraplegia Type 2 (SPG2) disorders of CNS myelination.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP329157.RAC7dwbrnLwJLc7FmdFFy6Rp3hneE3DgixiOyclmG8izA130_provenance.
• NP659124.RAQE9uYJoMB22lhEEmV-_rsSajmSeL2u9JjEv0GNeQ4NE130_assertion description "[Here we review the dosage effects and mutations of the proteolipid protein (PLP) gene that causes Pelizaeus-Merzbacher disease (PMD) and spastic paraplegia Type 2 (SPG2) disorders of CNS myelination.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP659124.RAQE9uYJoMB22lhEEmV-_rsSajmSeL2u9JjEv0GNeQ4NE130_provenance.
• NP878962.RA4TEsIbjPe5zBFopILwLvcjGrKy00wJ4oQMOZKxJhHYU130_assertion description "[Here we review the dosage effects and mutations of the proteolipid protein (PLP) gene that causes Pelizaeus-Merzbacher disease (PMD) and spastic paraplegia Type 2 (SPG2) disorders of CNS myelination.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP878962.RA4TEsIbjPe5zBFopILwLvcjGrKy00wJ4oQMOZKxJhHYU130_provenance.
• NP329146.RA5q4bXb-aVwgZ3UW9TrIIhFBYAZBr2P0x44RiKezn0zY130_assertion description "[Here we review the dosage effects and mutations of the proteolipid protein (PLP) gene that causes Pelizaeus-Merzbacher disease (PMD) and spastic paraplegia Type 2 (SPG2) disorders of CNS myelination.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP329146.RA5q4bXb-aVwgZ3UW9TrIIhFBYAZBr2P0x44RiKezn0zY130_provenance.
• assertion description "[Here we review the dosage effects and mutations of the proteolipid protein (PLP) gene that causes Pelizaeus-Merzbacher disease (PMD) and spastic paraplegia Type 2 (SPG2) disorders of CNS myelination.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Here we review the dosage effects and mutations of the proteolipid protein (PLP) gene that causes Pelizaeus-Merzbacher disease (PMD) and spastic paraplegia Type 2 (SPG2) disorders of CNS myelination.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Here we review the dosage effects and mutations of the proteolipid protein (PLP) gene that causes Pelizaeus-Merzbacher disease (PMD) and spastic paraplegia Type 2 (SPG2) disorders of CNS myelination.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Here we review the dosage effects and mutations of the proteolipid protein (PLP) gene that causes Pelizaeus-Merzbacher disease (PMD) and spastic paraplegia Type 2 (SPG2) disorders of CNS myelination.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Here we review the dosage effects and mutations of the proteolipid protein (PLP) gene that causes Pelizaeus-Merzbacher disease (PMD) and spastic paraplegia Type 2 (SPG2) disorders of CNS myelination.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Here we review the dosage effects and mutations of the proteolipid protein (PLP) gene that causes Pelizaeus-Merzbacher disease (PMD) and spastic paraplegia Type 2 (SPG2) disorders of CNS myelination.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Here we review the dosage effects and mutations of the proteolipid protein (PLP) gene that causes Pelizaeus-Merzbacher disease (PMD) and spastic paraplegia Type 2 (SPG2) disorders of CNS myelination.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Here we review the dosage effects and mutations of the proteolipid protein (PLP) gene that causes Pelizaeus-Merzbacher disease (PMD) and spastic paraplegia Type 2 (SPG2) disorders of CNS myelination.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP329149.RAHpoUSnvI6m6Nmf_8cu2eBjckfqGZNrEAueekX14QHvA130_assertion description "[Here we review the dosage effects and mutations of the proteolipid protein (PLP) gene that causes Pelizaeus-Merzbacher disease (PMD) and spastic paraplegia Type 2 (SPG2) disorders of CNS myelination.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP329149.RAHpoUSnvI6m6Nmf_8cu2eBjckfqGZNrEAueekX14QHvA130_provenance.
• NP329156.RAnd6h2CXBFcptZR7uCMX1lYUtwyjZPYRFKg36EXBFpsU130_assertion description "[Here we review the dosage effects and mutations of the proteolipid protein (PLP) gene that causes Pelizaeus-Merzbacher disease (PMD) and spastic paraplegia Type 2 (SPG2) disorders of CNS myelination.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP329156.RAnd6h2CXBFcptZR7uCMX1lYUtwyjZPYRFKg36EXBFpsU130_provenance.